Sobi acquires Synagis US rights from AstraZeneca - Pharmaceutical Business Review
Sobi acquires Synagis US rights from AstraZeneca Pharmaceutical Business Review
Swedish Orphan Biovitrum AB (Sobi) has completed the acquisition of US rights of Synagis (palivizumab) from AstraZeneca in a deal valued at around $1.6bn.
Comments
Post a Comment